RxDoctor Payments Data

Kirsten Bunce, MD

Family Medicine · Smyrna, TNNPI 1093750564

Payments from drug & device makers

$14,430in general payments, 2019–2025

Across 894 payments — averaging $16.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$858
  • GSK$706
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$14,33599%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk138$1,805
Amgen91$1,400
AbbVie(2 entities)77$1,399
AstraZeneca45$1,042
Pfizer64$858
GSK53$706
Boehringer Ingelheim35$561
Lilly USA, LLC41$555
Takeda Pharmaceuticals U.S.A., Inc.37$533
Bayer21$438
Otsuka America Pharmaceutical, Inc.20$422
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC33$402
Johnson & Johnson27$386
Astellas Pharma US Inc20$374
Eisai Inc.13$280
Esperion Therapeutics, Inc.14$245
Sanofi-aventis U.S. LLC16$227
Biohaven Pharmaceuticals, Inc.4$201
Exact Sciences13$199
Axsome Therapeutics, Inc.5$195
Merck10$168
Novartis9$163
Biohaven Pharmaceutical Holding Company Ltd.7$154
Teva Pharmaceuticals USA, Inc.9$130
Nestle Healthcare Nutrition Inc.7$129
Dexcom, Inc.7$123
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$100
Impel Pharmaceuticals Inc.5$83
Phathom Pharmaceuticals, Inc.4$73
Supernus Pharmaceuticals, Inc.4$73
Aimmune Therapeutics, Inc.4$69
Lundbeck LLC4$64
Shield Therapeutics Inc2$61
Jazz Pharmaceuticals Inc.4$60
Amarin Pharma, Inc.3$57
Edwards Lifesciences1$53
Inspire Medical Systems, Inc.2$52
Dynavax Technologies Corporation2$42
Arbor Pharmaceuticals, Inc.3$39
Zyla Life Sciences, Inc.3$37
Bausch Health US, LLC2$33
Daiichi Sankyo Inc.2$32
Sumitomo Pharma America, Inc.2$31
Cranial Technologies, Inc1$30
Xeris Pharmaceuticals, Inc.2$30
Radius Health, Inc.2$26
E.r. Squibb & Sons, L.L.C.2$26
Antares Pharma, Inc.2$22
Agios Pharmaceuticals, Inc.1$20
Avanir Pharmaceuticals, Inc.1$17
Insulet Corporation1$16
VBI Vaccine (delaware) Inc.1$16
Ironwood Pharmaceuticals, Inc1$15
IBSA Pharma Inc.1$15
Evoke Pharma, Inc.1$15
Boston Scientific1$15
Idorsia Pharmaceuticals US Inc1$14
Sun Pharmaceutical Industries Inc.1$14
Currax Pharmaceuticals LLC1$13
Clarus Therapeutics Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,430 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$81,198
Medicare patients
110
Services billed
1,783

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide64$100,439
MounjaroTirzepatide71$85,154
EliquisApixaban84$68,620
Trelegy ElliptaFluticasone/Umeclidin/Vilanter57$62,954
TymlosAbaloparatide23$58,660
FarxigaDapagliflozin Propanediol52$41,694
JardianceEmpagliflozin31$39,211
ZenpepLipase/Protease/Amylase14$37,402
LinzessLinaclotide23$29,572
ProliaDenosumab17$29,387
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog23$27,461
MyrbetriqMirabegron25$21,635
Soliqua 100-33Insulin Glargine/Lixisenatide14$17,614
RexultiBrexpiprazole12$17,325
Repatha SureclickEvolocumab11$14,911

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,805$114,74375 claims
Lilly USA, LLCMounjaro$555$85,15471 claims
PfizerEliquis, Premarin$858$73,56396 claims
GSKTrelegy Ellipta$706$62,95457 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$561$59,37961 claims
Radius Health, Inc.Tymlos$26$58,66023 claims
AstraZenecaFarxiga$1,042$41,69452 claims
Aimmune Therapeutics, Inc.Zenpep$69$37,40214 claims
AbbVieLinzess, Synthroid, Lumigan$1,399$36,85282 claims
AmgenProlia$1,400$29,38717 claims
Astellas Pharma US IncMyrbetriq$374$21,63525 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$227$17,61414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Smyrna

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →